A share price of Cogent Biosciences Inc [COGT] is currently trading at $12.37, up 1.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The COGT shares have gain 4.26% over the last week, with a monthly amount glided 4.48%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $17. Previously, Needham downgraded its rating to Hold on December 11, 2024. On February 26, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $8 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $11 on February 08, 2024. Wedbush downgraded its rating to a Neutral but $5 remained the price target by the analyst firm on December 11, 2023. JP Morgan started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $18. In a note dated April 28, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $20 on this stock.
Cogent Biosciences Inc experienced fluctuations in its stock price throughout the past year between $3.72 and $12.97. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $12.37 at the most recent close of the market. An investor can expect a potential return of 61.68% based on the average COGT price forecast.
Analyzing the COGT fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -69.82%, Pretax Profit Margin comes in at -66.19%, and Net Profit Margin reading is -66.19%. To continue investigating profitability, this company’s Return on Assets is posted at -1.03, Equity is -1.2 and Total Capital is -1.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.20 points at the first support level, and at 12.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.47, and for the 2nd resistance point, it is at 12.57.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cogent Biosciences Inc [NASDAQ:COGT] is 4.19. In addition, the Quick Ratio stands at 4.19 and the Cash Ratio stands at 2.18.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jul 10 ’25 when 2.78 million shares were purchased. Chief Commercial Officer, Pinnow Cole completed a deal on Jan 14 ’25 to buy 43750.0 shares.
